A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT04157517 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to futility.

Conditions

Neoplasms
Melanoma

Interventions

DRUG: Modakafusp Alfa
DRUG: Pembrolizumab

Sponsor

Teva Branded Pharmaceutical Products R&D LLC